智通财经网·2025-08-26 12:39Core Viewpoint - The announcement indicates that Sichuan Huiyu Pharmaceutical Co., Ltd. has approved a potential agency agreement for the core product TY-9591, which could enhance sales and market penetration in China [1] Group 1: Agreement Details - Sichuan Huichen Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sichuan Huiyu, may be appointed as the exclusive agent for TY-9591 in mainland China, with an initial milestone payment of up to RMB 150 million [1] - The potential agency arrangement is aimed at leveraging the existing sales and distribution network of Sichuan Huichen and Sichuan Huiyu [1] Group 2: Strategic Implications - The arrangement is expected to accelerate market penetration and reduce costs associated with establishing new sales channels for TY-9591 [1] - Collaborating with a well-established pharmaceutical company like Sichuan Huiyu is anticipated to strengthen the company's brand image in the market [1]